Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic

OneSource is the contract development and manufacturing organization (CDMO) partner for this product

FDA pushes forward on gene-editing therapies with new safety roadmap

Genome editing holds extraordinary promise for treating previously incurable genetic diseases

Precision BioSciences expands Hepatitis B gene editing trial into France and Romania

The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania

Galderma rolls out next-generation regenerating skin nectar

Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities

Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Healync Technologies secures Volrado Venture investment to build next-generation digital hospital infrastructure

Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform

Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development

A major push to sharpen the future of cancer treatment is underway

C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality

The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation

Orbicular, Apotex win tentative USFDA nod for generic Ozempic

Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection